303 related articles for article (PubMed ID: 18561967)
1. Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration.
León G; Segura A; Herrera M; Otero R; França FO; Barbaro KC; Cardoso JL; Wen FH; de Medeiros CR; Prado JC; Malaque CM; Lomonte B; Gutiérrez JM
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1115-9. PubMed ID: 18561967
[TBL] [Abstract][Full Text] [Related]
2. Anti-human erythrocyte antibodies in horse-derived antivenoms used in the treatment of snakebite envenomations.
León G; Rodríguez MA; Rucavado A; Lomonte B; Gutiérrez JM
Biologicals; 2007 Mar; 35(1):5-11. PubMed ID: 16490363
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms.
León G; Herrera M; Segura Á; Villalta M; Vargas M; Gutiérrez JM
Toxicon; 2013 Dec; 76():63-76. PubMed ID: 24055551
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune responses to venom and antivenom of patients bitten by Bothrops snakes.
Morais V; Berasain P; Ifrán S; Carreira S; Tortorella MN; Negrín A; Massaldi H
Toxicon; 2012 Feb; 59(2):315-9. PubMed ID: 22206812
[TBL] [Abstract][Full Text] [Related]
5. Intravenous administration of equine-derived whole IgG antivenom does not induce early adverse reactions in non-envenomed horses and cows.
Estrada R; Herrera M; Segura A; Araya J; Boschini C; Gutiérrez JM; León G
Biologicals; 2010 Nov; 38(6):664-9. PubMed ID: 20833066
[TBL] [Abstract][Full Text] [Related]
6. Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea.
Williams DJ; Jensen SD; Nimorakiotakis B; Müller R; Winkel KD
Toxicon; 2007 May; 49(6):780-92. PubMed ID: 17210167
[TBL] [Abstract][Full Text] [Related]
7. Production of anti-horse antibodies induced by IgG, F(ab')2 and Fab applied repeatedly to rabbits. Effect on antivenom pharmacokinetics.
Vázquez H; Olvera F; Alagón A; Sevcik C
Toxicon; 2013 Dec; 76():362-9. PubMed ID: 24047962
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom.
Segura A; León G; Su CY; Gutiérrez JM; Burnouf T
Biologicals; 2009 Oct; 37(5):306-12. PubMed ID: 19540775
[TBL] [Abstract][Full Text] [Related]
9. IgG subclass distributions of anti-horse serum antibodies and natural venom-antibodies produced in response to antivenom injection or snake bite in humans.
Ameno S; Ameno K; Fuke C; Kiryu T; Ijiri I
Toxicon; 1990; 28(3):347-50. PubMed ID: 2343468
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand.
Thiansookon A; Rojnuckarin P
Acta Trop; 2008 Feb; 105(2):203-5. PubMed ID: 17996842
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits.
Quesada L; Sevcik C; Lomonte B; Rojas E; Gutiérrez JM
Toxicon; 2006 Sep; 48(3):255-63. PubMed ID: 16863656
[TBL] [Abstract][Full Text] [Related]
12. Single-reagent one-step procedures for the purification of ovine IgG, F(ab')2 and Fab antivenoms by caprylic acid.
Al-Abdulla I; Casewell NR; Landon J
J Immunol Methods; 2014 Jan; 402(1-2):15-22. PubMed ID: 24246428
[TBL] [Abstract][Full Text] [Related]
13. A new ELISA for determination of potency in snake antivenoms.
Rial A; Morais V; Rossi S; Massaldi H
Toxicon; 2006 Sep; 48(4):462-6. PubMed ID: 16893558
[TBL] [Abstract][Full Text] [Related]
14. On the presence of antibodies against bovine, equine and poultry immunoglobulins in human IgG preparations, and its implications on antivenom production.
Sevcik C; Díaz P; D'Suze G
Toxicon; 2008 Jan; 51(1):10-6. PubMed ID: 18045635
[TBL] [Abstract][Full Text] [Related]
15. Human anti-snake venom IgG antibodies in a previously bitten snake-handler, but no protection against local envenoming.
Isbister GK; Halkidis L; O'Leary MA; Whitaker R; Cullen P; Mulcahy R; Bonnin R; Brown SG
Toxicon; 2010; 55(2-3):646-9. PubMed ID: 19647759
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab')(2), IgG and IgG(T) fragments from hyper immune equine plasma.
Vázquez H; Olvera F; Paniagua-Solís J; Alagón A; Sevcik C
Int Immunopharmacol; 2010 Apr; 10(4):447-54. PubMed ID: 20093203
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia.
Otero-Patiño R; Segura A; Herrera M; Angulo Y; León G; Gutiérrez JM; Barona J; Estrada S; Pereañez A; Quintana JC; Vargas LJ; Gómez JP; Díaz A; Suárez AM; Fernández J; Ramírez P; Fabra P; Perea M; Fernández D; Arroyo Y; Betancur D; Pupo L; Córdoba EA; Ramírez CE; Arrieta AB; Rivero A; Mosquera DC; Conrado NL; Ortiz R
Toxicon; 2012 Feb; 59(2):344-55. PubMed ID: 22146491
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin.
Chippaux JP; Massougbodji A; Stock RP; Alagon A;
Am J Trop Med Hyg; 2007 Sep; 77(3):538-46. PubMed ID: 17827375
[TBL] [Abstract][Full Text] [Related]
19. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies.
Seifert SA; Boyer LV
Ann Emerg Med; 2001 Feb; 37(2):189-95. PubMed ID: 11174238
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.
Gutiérrez JM; León G; Lomonte B
Clin Pharmacokinet; 2003; 42(8):721-41. PubMed ID: 12846594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
